OncoMatch/Clinical Trials/NCT06879379
KPD Consolidation After ASCT in NDMM Patients
Is NCT06879379 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation for multiple myeloma, newly diagnosed.
Treatment: KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation — This study aims to evaluate the efficacy and safety of post-transplant consolidation therapy with the KPD regimen (carfilzomib, pomalidomide, and dexamethasone) versus no consolidation, followed by maintenance therapy, in patients with transplant-eligible newly diagnosed multiple myeloma (TE-NDMM). The primary goal is to compare minimal residual disease (MRD) negativity rates and overall treatment outcomes between the two groups.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: triplet or quadraplet induction regimen — upfront
Received upfront triplet or quadraplet induction regimen
Must have received: autologous stem cell transplant — upfront
Received upfront ASCT after induction
Lab requirements
Liver function
ALT/AST ≤ 2.5 × UNL; serum total bilirubin ≤ 1.5 × UNL (if congenitally high bilirubin, direct bilirubin ≤ 1.5 × UNL)
Cardiac function
LVEF ≥ 50% as diagnosed by echocardiography, with no clinically significant ECG abnormalities
Adequate Organ Function Reserve: ALT/AST ≤ 2.5 × UNL; serum total bilirubin ≤ 1.5 × UNL (if congenitally high bilirubin, direct bilirubin ≤ 1.5 × UNL); LVEF ≥ 50% as diagnosed by echocardiography, with no clinically significant ECG abnormalities; basal oxygen saturation > 95% in room air
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06879379 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received triplet or quadraplet induction regimen and autologous stem cell transplant.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages